Bucindolol
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
|
|
| CAS Number | 71119-11-4 |
| PubChem (CID) | 51045 |
| ChemSpider | 46266 |
| UNII | E9UO06K7CE  |
| ChEMBL | CHEMBL2107546 |
| ECHA InfoCard | 100.114.291 |
| Chemical and physical data | |
| Formula | C22H25N3O2 |
| Molar mass | 363.45 g/mol |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]
See also[edit]
References[edit]
- ^ a b "formularyjournal.modernmedicine.com".
- ^ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
- ^ "FDA rejects bucindolol and questions trial integrity « CardioBrief".
 |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
